FDA approves supplemental patient cohort for HeartWare's Endurance trial

|By:, SA News Editor

The FDA approves and IDE supplement allowing HeartWare International (HTWR -0.6%) to enroll an additional patient cohort for the Endurance destination therapy study.

Data from the new cohort will be included in a PMA application seeking a destination therapy indication for the HeartWare System. (PR)

More on the Endurance trial: Northland sees "glaring inconsistencies."